Multimorbidity and Sarcopenia Feasibility Study in Chronic Kidney Disease (MaSS-CKD)

University Hospitals of Derby and Burton NHS Foundation Trust

Status: Not yet enrolling

Conditions: Chronic Kidney Diseases; Sarcopenia

Treatments: Diagnostic Test: Cystatin C eGFR; Other: Bioimpedance Analysis (Body composition analysis)

Study type: Observational

Funder types: Other

Identifiers

NCT06109662

328554

Details and patient eligibility

About

The aim of this research study is to look at the body composition (such as muscle and fat) in people with chronic kidney disease (CKD) and comparing it with body composition is people without CKD. The investigators currently understand loss of muscle function and mass (sarcopenia) affect the general health of people as they age, but this process seems to be more common, accelerated, and occurs earlier in people with CKD. There is limited evidence in this area, and we believe that if we understand when and how sarcopenia affects people with CKD, investigators can guide future trials and treatments to help treat sarcopenia, and in turn improve quality of life and health outcomes in people with CKD.

Full description

In this study, the investigators will follow up people with CKD in two visits a year apart. In both visits, the investigators will measure the participants body composition and estimated kidney function using 2 different testing methods - Cystatin C eGFR and Creatinine eGFR. Using both the results in a formula, the creatinine muscle index can be calculated. If this index correlated with sarcopenia, it will be helpful tool in the care of people with CKD as will be a easy to use screening tool for sarcopenia in this population.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Subjects capable of giving informed consent

≥18 years of age Chronic kidney disease stages 3-5 looked after in secondary care nephrology Healthy volunteers with normal kidney function (Control)

Exclusion criteria

• Pregnancy
• Subjects with known neuromuscular diseases, e.g. myopathy, muscular dystrophy, muscular atrophy
• Renal transplant recipients
• Patients with pacemakers

Trial design

80 participants in 4 patient groups

Healthy volunteers

Description:

Normal renal function with no kidney disease. Participants with other comorbidities can be included as long as not listed on the exclusion criteria. They will have body composition measured, and eGFR measured.

Treatment:

Other: Bioimpedance Analysis (Body composition analysis)

Diagnostic Test: Cystatin C eGFR

Chronic Kidney Disease Stage 3

Description:

People with CKD Stage 3 (eGFR 30-59). They will have body composition measured, and eGFR measured.

Treatment:

Other: Bioimpedance Analysis (Body composition analysis)

Diagnostic Test: Cystatin C eGFR

Chronic Kidney Disease Stage 4

Description:

People with CKD 4 (eGFR 15-29). They will have body composition measured, and eGFR measured.

Treatment:

Other: Bioimpedance Analysis (Body composition analysis)

Diagnostic Test: Cystatin C eGFR

Chronic Kidney Disease Stage 5

Description:

People with CKD 5 (eGFR \<15), but not on dialysis. They will have body composition measured, and eGFR measured.

Treatment:

Other: Bioimpedance Analysis (Body composition analysis)

Diagnostic Test: Cystatin C eGFR